Related references
Note: Only part of the references are listed.The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Eric L. Ross et al.
CLINICAL INFECTIOUS DISEASES (2015)
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Paula M. Luz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000-2010
Sayonara R. Ribeiro et al.
ANTIVIRAL THERAPY (2014)
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011
David A. Martin et al.
BMC INFECTIOUS DISEASES (2014)
The Survival Benefits of Antiretroviral Therapy in South Africa
Michael D. April et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics
Alexandre Grangeiro et al.
PLOS ONE (2014)
Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil
Sandra W. Cardoso et al.
AIDS RESEARCH AND THERAPY (2014)
Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Rochelle P. Walensky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Measuring Adherence to Antiretroviral Treatment: The Role of Pharmacy Records of Drug Withdrawals
Eliana Battaggia Gutierrez et al.
AIDS AND BEHAVIOR (2012)
Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries
Stephen Resch et al.
PLOS ONE (2011)
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
Jean-Michel Molina et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients
Farzad Noubary et al.
STATISTICS IN MEDICINE (2010)
Differential Survival Benefit of Universal HAART Access in Brazil: A Nation-Wide Comparison of Injecting Drug Users Versus Men Who Have Sex With Men
Monica Malta et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
The National Response to the HIV/AIDS Epidemic in Peru: Accomplishments and Gaps - A Review
Carlos F. Caceres et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Characterization of virologic failure after an initially successful 48-week course of antiretroviral therapy in HIV/AIDS outpatients treated in Santos, Brazil
Marcos M. Caseiro et al.
Brazilian Journal of Infectious Diseases (2008)
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients - 144-week analysis
Jose R. Arribas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Scaling up antiretroviral therapy in South Africa: The impact of speed on survival
Rochelle P. Walensky et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Jose Valdez Madruga et al.
LANCET (2007)
Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives
Dirceu B. Greco et al.
AIDS (2007)
Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil
Patricia Braga et al.
AIDS PATIENT CARE AND STDS (2007)
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection
Benigno Rodriguez et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Cost-effectiveness of HIV treatment in resource-poor settings - The case of Cote d'Ivoire
Sue J. Goldie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The survival benefits of AIDS treatment in the United States
Rochelle P. Walensky et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M Johnson et al.
AIDS (2006)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003
DP Campos et al.
AIDS (2005)
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations
B Clotet et al.
AIDS (2004)
Dramatic improvement in survival among adult Brazilian AIDS patients
JRP Marins et al.
AIDS (2003)
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
MA Albrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The cost effectiveness of combination antiretroviral therapy for HIV disease.
KA Freedberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
